Lipids & metabolic liver disease
Association between triglyceride–glucose index trajectories and radiofrequency ablation outcomes in patients with stage 3D atrial fibrillation
Main finding · AF recurrence after RFCAResult — go to the resultHazard ratio 1.580 95% CI 1.146–2Authors' conclusion
The TyG trajectories in patients with stage 3D AF are significantly linked to the outcomes of AF recurrence. Continuous monitoring of TyG levels during follow-up may help in identifying patients at high risk of AF recurrence, enabling the early application of effective interventions.
Study context
- Population
- Patients with stage 3D atrial fibrillation (AF) undergoing radiofrequency catheter ablation, Fourth Affiliated Hospital of Zhejiang University and Taizhou Hospital of Zhejiang Province, January 2016 to December 2022; mean age 63.21 ± 9.84 years, 63.19% male200 AF recurrences
- Participants
- 997 patients
- Exposure
- Triglyceride-glucose (TyG) index trajectory groups
- Locus 1 low-lown = 791reference
- Locus 2 low-high-lown = 14
- Locus 3 high-highn = 192
- Outcome
- Atrial arrhythmia for at least 30 s after a 3-month period post-ablation (AF recurrence)
- Follow-up
- Mean 30.43 ± 17.75 months
Methodological detailstwo-centre, latent class trajectory model
- Two-centre
- Latent class trajectory model
Main finding
AF recurrence after Radiofrequency Catheter Ablation (RFCA)
Hazard ratio
1.580
95% CI 1.146–2
Locus 3vs Locus 1
HR 1.580 (95% CI 1.146–2)
As reported in the abstract
- Significant differences in survival rates among the trajectories (Kaplan-Meier)
- P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| AF recurrence, TyG >9.37vs <8.67 | 2.056 (1.335–3.166) | |
| 0.20.5125Hazard ratio (log scale) |
Baseline TyG level and AF recurrence
- HR (multivariate Cox), 95% CI 1.087-1.448
- 1.255
Original publication
Association between triglyceride–glucose index trajectories and radiofrequency ablation outcomes in patients with stage 3D atrial fibrillation. Cardiovasc Diabetol. Published 5 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →